Waltham, Massachusetts-based Adagio Therapeutics Inc, a developer of best-in-class antibodies, has raised $80 million in Series B financing. GV led the round with participation from Polaris Partners, Mithril Capital, Fidelity Management & Research Company, LLC, OrbiMed, Population Health Partners and Omega Funds.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: